What Researchers Did
Researchers investigated the effect of hyperbaric oxygen therapy (HBOT) on blood levels of cytokines, vascular endothelial growth factor (VEGF), and arginine derivatives in 80 patients with necrotizing soft-tissue infections, aseptic bone necrosis, or idiopathic sudden sensory neural hearing loss.
What They Found
The study found no significant changes in blood concentrations of inflammatory cytokines (IL-1, IL-4, IL-6, IL-10, TGF-β), vascular endothelial growth factor (VEGF), or arginine derivatives after hyperbaric oxygen therapy. These findings suggest that HBOT does not induce inflammation or endothelial injury in the 80 patients studied.
What This Means for Canadian Patients
Canadian patients undergoing hyperbaric oxygen therapy for conditions like necrotizing soft-tissue infections or aseptic bone necrosis may be reassured that the treatment does not appear to induce inflammation or endothelial injury. This information supports the safety profile of HBOT concerning these specific biological markers.
Canadian Relevance
This study has no direct Canadian connection as it was not conducted in Canada, nor did it involve Canadian researchers or patients.
Study Limitations
A limitation of this study is that it focused on a specific set of biomarkers and patient populations, and the long-term effects of HBOT on these parameters were not assessed.